Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.63 |
| ▸ | CNR1 | P21554 | 6/20 | 0.63 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961519 | 0.79 | CNR2 (0.74) | CNR2CNR1FAAHHPGDALDH1A1 | |
| SCHEMBL3687436 | 0.77 | CNR2 (1.00) | CNR2CNR1FAAHHSD11B1KMT2A | |
| SCHEMBL16404214 | 0.76 | USP30 (0.54) | CNR2CNR1FAAHHSD11B1KMT2A | |
| SCHEMBL21314950 | 0.73 | NOTUM (0.50) | HPGDALDH1A1 | |
| SCHEMBL16404249 | 0.73 | CNR2 (0.78) | CNR2CNR1HSD11B1LMNAHPGD | |
| SCHEMBL1675682 | 0.70 | KMT2A (0.74) | CNR2CNR1FAAHHSD11B1KMT2A | |
| SCHEMBL3067075 | 0.70 | HSD11B1 (0.61) | CNR2CNR1HSD11B1 | |
| SCHEMBL3455510 | 0.70 | GRM5 (0.58) | CNR2CNR1FAAHHSD11B1KMT2A | |
| SCHEMBL13634586 | 0.69 | NPC1 (0.56) | CNR2CNR1FAAHHSD11B1KMT2A | |
| SCHEMBL6084283 | 0.69 | SMN1; SMN2 (0.52) | CNR2CNR1FAAHHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937184-B2 | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators | ABBVIE B.V. (NL) | 2015-01-20 | — | — | US | disclosed |
| US-20060194779-A1 | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators | ABBVIE B.V. (NL) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194779-A1 | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators | CNR1, CNR2, HRH4 | CNR2 2/4885CNR1 1/4885FAAH 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.